Cardiovascular disease in diabetes: Prevention and intervention

Current Opinion in Endocrinology and Diabetes

Volumn 8, Issue 2, 2001, Pages 101-110

  Goldberg, R B ^a   Florez, H ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; EXERCISE TEST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; MORBIDITY; MORTALITY; REVIEW; RISK FACTOR; RISK MANAGEMENT; SCREENING TEST;

EID: 0035104134     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200104000-00008     Document Type: Review

References (85)

1. Diabetes and cardiovascular disease. The Framingham Study
2. Diabetes and decline in heart disease mortality in US adults
3. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association
4. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?
5. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state
6. Impaired glucose tolerance, insulin resistance and cardiovascular disease
7. The Diabetes Prevention Program: Baseline characteristics of the randomized cohort
8. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
9. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
10. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction
11. Prevention Conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention. Executive summary
12. Carotid artery atherosclerosis in type 2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study)
13. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
14. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: The Kuopio Ischemic Heart Disease Risk Factor Study
15. Cardiovascular risk factors clustering with endogenous hyperinsulinemia predict death from coronary heart disease in patients with type 2 diabetes
16. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population
17. Hyperglycemia and cardiovascular disease in patients with type 2 diabetes
18. Obesity/insulin resistance is associated with endothelial dysfunction
19. Increased levels of soluble vascular cell adhesion molecule 1 are associated with risk of cardiovascular mortality in type 2 diabetes. The Hoom Study
20. Low cardiorespiratory fitness and physical inactivity as predictors of mortality in men with type 2 diabetes
21. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
22. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
23. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups
24. A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucose level-lowering
25. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes
26. Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study
27. Ten year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in type 2 (non-insulin-dependent) diabetic and non-diabetic subjects
28. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
29. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyzes in the cholesterol and recurrent events (CARE) trial
30. Effects of aggressive cholesterol lowering and low dose anticoagulation on clinical and angiographic outcomes in patients with diabetes. The Post Coronary Artery Bypass Graft Trial
31. Management of dyslipidemia in adults with diabetes
32. Cost effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated?
33. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein choresterol goals
34. Triglyceride is the major atherogenic lipid in NIDDM
35. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM
36. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: Implications for treatment
37. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High Density Lipoprotein Cholesterol Intervention Trial Study Group
38. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study
39. The Diabetes Atherosclerosis intervention Study (DAIS): A study conducted in cooperation with the World Health Organization
40. Mechanism of action of fibrates on lipid and lipoprotein metabolism
41. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT Study: A Randomized Trial
42. Management of patients with hypertension and diabetes mellitus. Advances in the evidence for intensive treatment
43. End-stage renal disease in African-American and white men. 16-year MRFIT findings
44. The sixth report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure
45. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension
46. Major cardiovascular events in hypertensive patient randomized to doxazosin versus chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
47. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomized trial
48. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
49. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
50. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE and MICRO-HOPE substudy
51. The cost effectiveness of treating all patients with type 2 diabetes with ACE inhibitors
52. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators
53. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomized trial
54. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
55. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM
56. Preserving renal function in adults with hypertension and diabetes: A consensus approach
57. The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: A population-based analysis from the Health Surveys for-England 1991-94
58. Fibrin(ogen) and diabetes mellitus: Don't forget fibrinolysis
59. The role of platelets in diabetes-related vascular complications
60. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women, Heart and Estrogen Replacement Study (HERS) Research Group
61. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
62. Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance
63. Aspirin therapy in diabetes
64. Aspirin therapy in diabetes. American Diabetes Association
65. Body mass index, diabetes, and C-reactive protein among U.S. adults
66. Prevention Conference V. Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Noninvasive tests of atherosclerotic burden: Writing Group III
67. Diabetes Mellitus. Subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality
68. Coronary calcium in adults with type 1 diabetes. A stronger correlate of clinical coronary artery disease in men than in women
69. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes
70. Silent myocardial ischemia in patients with diabetes
71. Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus
72. Primary stenting in acute MI: Influence of diabetes mellitus in angiographic results and clinical outcome
73. Diabetes and acute myocardial infarction: The role of insulin therapy
74. Effect of insulin-glucose infusion on left ventricular function at rest and during dynamic exercise in healthy subjects and non-insulin-dependent diabetic patients
75. B-blocker therapy for secondary prevention of myocardial infarction in elderly diabetic patients
76. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: The data from the GISSI-3 study
77. Acute myocardial infarction in diabetes mellitus. Lessons learned from ACE inhibition
78. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction
79. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction
80. Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST)
81. Effects of coronary artery bypass grafting using internal mammary arteries for diabetic patients
82. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status
83. Restenosis rates in diabetic patients. A comparison of coronary stenting and balloon angioplasty in native coronary vessels
84. Optimizing the percutaneous outcomes for patients with diabetes mellitus. Results of the EPISTENT Diabetic Substudy
85. Abciximab reduces mortality in diabetics following percutaneous coronary intervention